SlideShare une entreprise Scribd logo
1  sur  72
Télécharger pour lire hors ligne
Approach To A Child
With Short Stature
Moderated by Dr. Mohd. Haseeb Sir
Presented by Dr. Akshay Golwalkar
Why we need to concern?
BECAUSE…………………..
IT CAN BE A SIGN OF DISEASE,
DISABILITY
&
A SOCIAL STIGMA CAUSING
PSYCHOLOGICAL STRESS

Definition*
Height below 3rd centile or less than 2 standard
deviations below the median height for that age &
sex according to the population standard
OR
Even if the height is within the normal percentiles
but growth velocity is consistently below 25th
percentile over 6-12 months of observation or
Excessively short for mid mid parental or target
height
Males
Age (y )
30
34
38
42
46
50
54
58
62
66
70
74
78
Height(in)
Height(cm)
2 4 6 8 10 12 14 16 18 20
70
80
90
100
110
120
130
140
150
160
170
180
190
200
0
+2
+1
-1
-2
-2.0 SD (2.3 percentile)
*Essential Pediatrics, 7th Edition OP Ghai; IAP spatiality series Endocrinology 2nd edition
Approximately 3% children in any population will be short*
Approximately half will be physiological ( familial or
constitutional ) & half will be pathological short stature*
Most common cause is malnutrition in developing
countries*
Familial or constitutional is the leading cause in
developed countries*
*IAP spatiality series Endocrinology 2nd edition
Growth Physiology
Growth
Environment
HormonesGenetic factors
Dietary factors
•Growth hormone
•Thyroid hormone
•Gonadotrophins
Factors affecting height
Intra
uterine
Growth
factors
Nutrition
Thyroid harmone
Growth Hormone
FSH
LH
GH
Thyroid
Birth 1 year 2 years 4years 8years Puberty Adult
Endocrinology of Postnatal Growth
Deficiency of thyroxin
blunts GH secretion.
GROWTH
Linear
Growth
Ponderal
Growth
Skeletal maturation
& Bone Growth
Linear Growth
Increased Growth
Velocity @ puberty
Etiology of short stature*
Physiological
– Familial
– Constitutional short stature
Pathological
– undernutrition
– Chronic systemic illness
– Hormonal deficiency states
– Psychosocial dwarfism
– SGA
– Skeletal dysplasias
– Genetic syndromes
*Essential Pediatrics, 7th Edition OP Ghai; IAP spatiality series Endocrinology 2nd edition
Familial Vs Constitutional*
Feature Familial Short Stature Constitutional Short Stature
1) Sex Both equally affected More common in boys
2) Family History Of short stature Of delayed puberty
3) Height Velocity Normal Normal
4) Puberty Normal Delayed
5) Bone Age Normal Less than
chronological age
6) Final Height Short, but normal for
target
height
Normal
*IAP spatiality series Endocrinology 2nd edition
Approach to a child with short stature
History & “observation”
Anthropometric measurements
Plotting on growth chart
Physical examination
workup
History
Birth history
Nutritional history
Chronic disease history (asthma, CHD,
CLD,CRF, chronic diarrhea)
Drugs….chronic steroid therapy
Family history
History Etiology
History of delay of puberty in parents Constitutional delay of growth
Low Birth Weight SGA
Neonatal hypoglycemia, jaundice, micropenis GH deficiency
Dietary intake Under nutrition
Headache, vomiting, visual problem Pituitary/ hypothalamic SOL
Lethargy, constipation, weight gain Hypothyroidism
Polyuria CRF, RTA
Social history Psychosocial dwarfism
Diarrhea, greasy stools Malabsorption
Clues to etiology from history
Pointer Etiology
Midline defects, micropenis, Frontal
bossing, depressed nasal bridge,
crowded teeth,
GH deficiency
Rickets Renal failure, RTA, malabsorption
Pallor Renal failure, malabsorption, nutritional anemia
Malnutrition PEM, malabsorption, celiac disease, cystic fibrosis
Obesity Hypothyroidism, Cushing syndrome, Prader Willi
syndrome
Metacarpal shortening Turner syndrome, pseudohypoparathyroidism
Cardiac murmur Congenital heart disease, Turner syndrome
Mental retardation Hypothyroidism, Down/ Turner syndrome,
pseudohypoparathyroidism
Pointers to etiology of short stature
1) Accurate height measurement
Below 2 yrs*- supine length with
infantometer.
Assessment of a child with short stature
*IAP spatiality series Endocrinology 2nd edition
Assessment of a child with short stature
For older children-
Harpenden Stadiometer
Height measurements
Without footwear
Heels & back touching
the wall
Looking straight ahead
Growth chartTarget centiles
Increments in Height*
Age Increase in height
Birth 50cm
1st yr age 25cm
2nd yr age 10cm
3rd yr age 7.5cm
4th yr age 5cm
5th yr age 5cm/year
*IAP spatiality series Endocrinology 2nd edition
Growth Velocity*
The most critical factor in evaluating the growth is
determining GROWTH VELOCITY.
Observation of childs height pattern in the form of
“CROSSING PERCENTILE LINES” on a linear
growth curve is the simplest method of observing
abnormal growth velocity.*
*IAP spatiality series Endocrinology 2nd edition
At least 3 measurements with preferably 6 months
interval in between is necessary to comment on
growth pattern.*
*IAP spatiality series Endocrinology 2nd edition
Growth Velocity*
Growth Monitoring*
Age Ht/Length Wt Head
circumference
Others
Birth Yes Yes Yes --
1.5, 3.5
6, 9, 15 mths
Yes Yes Yes --
1.5 to 3 yrs 6 monthly 6 monthly 6 monthly Mid arm
3.5 to 5.5 yrs 6 monthly 6 monthly --
6 to 8 yrs 6 monthly 6 monthly -- BMI & SMR
9 to 18 yrs Yearly Yearly -- BMI & SMR
yearly
*IAP spatiality series Endocrinology 2nd edition
Target height*
Target height in cm for a girl = [(mother's height
in cm + father's height in cm) /2] - 6.5 cm
Target height in cm for a boy = [(mother's height
in cm + father's height in cm) /2] + 6.5 cm
*IAP spatiality series Endocrinology 2nd edition
Short Child That Looks Normal*
Normal growth velocity Low growth velocity
Low birth weight
Growth delay
Idiopathic SS
Chronic systemic disease
Endocrine disorder
Genetic, chromosomal
Psychosocial
Calculate the
target height
Within Target RangeNot Within Target Range
Watch GV Observe – GV Normal
Assessment of body proportion
Lower segment (LS) pubic symphysis to ground
Upper segment (US) total height/length – LS
US to LS ratio is 1.7 at birth decreases by 0.1
every year to reach 1 at 7 to 10 years of age.*
*IAP spatiality series Endocrinology 2nd edition
Arm span
Upper segment: Lower segment ratio
Increase :
– Achondroplasia
– Skeletal dyspalsias
– untreated hypothyroidism
Decreases :
– Short trunk (scoliosis)
– Short neck (klippel-Feil syndrome)
– Arachnodactyly (Marfan’s, homocystinuria)
Assessment of body proportion
Physical examination
Weight measurement (fat & short….endocrine,
thin & short……under nutrition or chronic illness)
Systemic examination to rule out systemic illness
skeletal system examination including spine
Dysmorphic features
Tanner staging
Clues to etiology from examination*
Examination finding Etiology
Disproportion Skeletal dysplasia, rickets, hypothyroidism
Dimorphism Congenital syndromes
Pallor Chronic anemia, chronic renal failure
Hypertension Chronic renal failure
Frontal bossing, depressed nasal bridge,
crowed teeth, small penis
Growth hormone deficiency
Goiter, coarse skin Hypothyroidism
Central obesity, striae Cushing syndrome
*Essential Pediatrics, 7th Edition OP Ghai;
Workup for short stature
Level 1* ( essential investigations):
Complete hemogram with ESR
Urinalysis
Stool
Blood
BONE AGE
*IAP spatiality series Endocrinology 2nd edition
Bone age assessment should be done
in all children with short stature
Appearance of various epiphyseal
centers & fusion of epiphyses with
metaphyses tells about the skeletal
maturity of the child
Bone Age (BA)
What does bone age tell you?
Skeletal maturity
Correlates closely with SMR
Speaks for remaining growth potential
Helps in adult height prediction
Bone age delay of more than 2 SD i.e. about 2
years is significant
Methods of bone age assessment
Tanner White House
Greulich and Pyle
TW Method - 13 Bones
G & P Method
Patient’s film is
compared with the
standard of the
same sex and
nearest age
It is next
compared with
adjacent standard,
both older and
younger to get the
closest match
Bone age gives an idea as to what proportion of adult
height has been achieved by the child & what is remaining
potential for height gain*
BA is delayed compared to chronological age in almost all
causes of short stature*
Exceptions: Familial short stature, Precocious puberty
*IAP spatiality series Endocrinology 2nd edition
Delayed bone age
Constitutional short stature
Hypothyroidism
Celiac disease
GH deficiency
Level 2*:
Serum thyroxine, TSH
Karyotype to rule out Turner syndrome in girls
If above investigations are normal and height between -2 to
-3 SD Observe height velocity for 6-12 months
Workup for short stature
if Level 1 investigations are normal and bone age is delayed proceeds to
level 2*
*IAP spatiality series Endocrinology 2nd edition
HYPOTHYROIDISM
Short, stocky child, dull looking, puffy face.
Thickened skin giving myxomatous appearance,
cold intolerance.
Protuberant abdomen with umbilical hernia
Infantile sexual development & delayed puberty
Bone age markedly delayed
Diagnosis- Low T4 levels, high TSH levels*
*IAP spatiality series Endocrinology 2nd edition
HYPOTHYROIDISM
CONGENITAL
(UNTREATED):
 Slow growth vel.
 Delayed BA
 Constipation
 Mental retardation
unless treated at 2-3
months.
ACQUIRED(UNTREATED)
 Asymptomatic
 Delayed growth
 Constipation
 Normal IQ if developed
after 2yrs of age
 Dry skin
Ideally every neonate should be screened for
TSH levels before discharging from nursery.*
Regardless of symptoms all children with
significant short stature should be screened for
hypothyroidism.*
Rx: thyroxine according to the age appopriate
dosage
HYPOTHYROIDISM
*IAP spatiality series Endocrinology 2nd edition
Turners syndrome
Short stature may be the only clinical
manifestation.
Karyotyping should be considered in a short
female child with pubertal delay.
SHOX gene which is required for the normal
growth is present only in a half a dose in these
children
 Webbed neck
 Short metacarpals
 Shield shaped chest
 Hyperconvex finger n toe nails
 Cubitus valgus with wide carrying angle of arms
 Gonadal dysgenesis with incomplete or absent
puberty
 No pubertal growth spurt.
Level 3*:
GH stimulation test with Clonidine or insulin & serum
insulin like GF-1 levels
Neuroimaging
Celiac serology ( anti- endomysial or anti- tissue
transglutaminase antibodies)
Duodenal biopsy
If height < -3 SD → proceeds to level 3 investigations*
*IAP spatiality series Endocrinology 2nd edition
GROWTH HORMONE DEFICIENCY(GHD)
Normal length & weight at birth.
Growth delay seen >1yr of age
BA < CA by at least 2 yrs
Normal intelligence & delayed BA.
Infantile gonadal development
Growth hormone actions
Growth Hormone
GH receptors
Liver
Synthesis of IGF1
Metabolic effects
IGF receptors
Growth Hormone
GH receptors
GH receptors Liver
Synthesis of IGF1
Proliferation of Cells
Cellular growth
Linear growth
Metabolic effects
(Anabolic)
IGF receptors
GROWTH HORMONE DEFICIENCY(GHD)
CONGENITAL:
-Perinatal asphyxia,
-CNS malformations
(septo optic dysplasia)
ACQUIRED
-idiopathic
-tumors
( craniopharyngioma,
glioma, germinoma)
-trauma/surgery
-cns infection/irradiation
Physical features
Cherubic face; fair complexion
Normal IQ
Frontal bossing
Midfacial crowding
Truncal obesity
Micropenis
Workup for GH def
GH deficiency is diagnosed by a low level of serum
insulinlike growth factor-1 (IGF-1) in the presence of
deficiency of 3 or more pituitary hormones*.
Patients who have deficiency of 2 or less pituitary
hormones or pituitary-hypothalamic disease with low
IGF-1 levels require stimulation tests to establish the
diagnosis of GH deficiency*.
*Hartman ML, Crowe BJ, Biller BM, Ho KK, Clemmons DR, Chipman JJ. Which patients do not require a
GH stimulation test for the diagnosis of adult GH deficiency?. J Clin Endocrinol Metab. Feb 2002;87(2):477-
85.
Workup for GH def
GH stimulation test
Insulin-induced hypoglycemia is the most
powerful stimulus for GH secretion; however,
this test also carries the greatest potential for
harm*.
Alternate GH stimulants: Arginine*, levodopa,
Propranolol with glucagon, Exercise, Clonidine,
Epinephrine.
*Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML,. Evaluation and treatment of adult growth hormone
deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. Jun 2011;96(6):1587-609
GH stimulation test
INTERPRETATION:
Peak stimulated growth hormone conc. <5.1ng/ml*
in response to GH stimulation test or
<11.1 ng/ml in response to combined Arg- GHRH
stimulation test with patients having BMI less
than 25*.
*Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML,. Evaluation and treatment of adult growth hormone
deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. Jun 2011;96(6):1587-609
IGF-1 and IFGBP-3 measurement*
IGFBP-3 and IGF-1 serum levels represent a
stable and integrated measurement of GH
production and tissue effects
IGF-1 have superior diagnostic sensitivity and
specificity compared with IGFBP 3.
The combination of IGF-1 and IGFBP-3
measurements is superior when compared to
individual tests
Workup for GH def
*IAP spatiality series Endocrinology 2nd edition
Interpretation of results*
If IGF-1 and IGBP-3 level are normal then it shows
that GH level is also normal (no need for GH testing)
If IGF-1 and IGBP-3 level are low then it may be due
to GH def or GH resistance-----go for GH basal level
and after stimulation
If GH also low then GH def, if normal or high then GH
resistance ( Primary IGF-1 def)
*IAP spatiality series Endocrinology 2nd edition
growth hormone therapy*
Currently approved as per FDA IN:
GHD
TURNERS SYNDROME
RENAL INSUFFIENCY
PRADER WILLE SYNDROME
NORMAL CHILDREN WITH HEIGHT <2.4 SD
SGA who have not reached 5th centile by 2yrs.
Shox (short stature homeobox gene)deficiency.
*IAP spatiality series Endocrinology 2nd edition
GH THERAPY*
DOSE: 0.1U/KG/DAY s.c. at night time
Follow up & watch for at least one year before
starting the treatment.
Earlier is always better & ideal is 3-4yrs
Never delay beyond 7-8yrs
Usually growth velocity is maximum in first year
of therapy.
*IAP spatiality series Endocrinology 2nd edition
Devices:
Freeze dried – commonest
Liquid prep- easy to administer
GH THERAPY
Automated pen type
G H THERAPY
 Routes of administration:
S.c- currently using
Intranasal- under trials
Timing: 2-3 times/wk
 Response to Rx:
Max response in 1st year with growth velocity >95th percentile
With each increasing year the growth rate tends to decline.
If falls <25th percentile: assess compliance before increasing
dose.
CRITERIA FOR STOPPING Rx:*
 Decision by patient that he/she is tall enough
 Growth rate <1 inch/year
BA >14YRS in girls & 16yrs in boys.
*IAP spatiality series Endocrinology 2nd edition
FOLLOWUP:*
 required as there is risk of :primary hypothyroidism /
adrenal insuffiency so periodic follow up needed.
SIDE EFFECTS:*
 Pseudotumour cerebri, hyperglycemia, acute
pancreatitis, liver abnormalities, gynaecomastia,
*IAP spatiality series Endocrinology 2nd edition
Take Home Message
Take height properly along with the height of parents
Plot on Growth Charts and find out the target centile
Determine the growth velocity by follow up at least after 6
months
A systematic approach and simple tests like bone age
usually reduce the need & hence cost of further
investigations
For dynamic stimulation tests refer the child to specialist
centres
SHORT STATURE
Dysmorphic Normal
•Russle Silver
•Noonan’s
•Turner syndrome
•Downs syndrome
•Prader Willi
•Pseudo-
hypoparathyroidism
Proportionate
Dis-
Proportionate
•Constitutional
•Familial/genetic
•IUGR
•Ch Malnutrition
•Celiac Disease
•Chronic systemic
disease (CRF, CLD)
•GH Deficiency
•Hypogonadism
•Hypothyroidism
•Osteogenesis
imperfecta
•Achodroplasia
•Rickets
•Metabolic and
storage disorders
(short spine)
Level 1 ( essential investigations):
1.Complete hemogram with ESR
2.BONE AGE
3.Urinalysis ( Microscopy, pH, Osmolality)
4.Stool ( parasites, steatorrhea, occult blood)
5.Blood ( RFT, Calcium, Phosphate, alkaline phosphatase, venous gas, fasting sugar,
albumin, transaminases)
Level 2 (investigations for short stature)
1.Serum thyroxin, TSH
2.Karyotype to rule out Turner syndrome in girls
Above is normal and bone age is delayed proceeds to level 2
• If above investigations are normal and height between -2 to -3→
observe height velocity for 6-12 months
• If height < -3 SD → proceeds to level 3 investigations
Approach to a child with short stature AG

Contenu connexe

Tendances

Shortstature sandip
Shortstature sandipShortstature sandip
Shortstature sandipSandip Gupta
 
Childhood hypertension
Childhood  hypertensionChildhood  hypertension
Childhood hypertensionHemraj Soni
 
Delayed puberty , etiology , diagnostic approach
Delayed puberty , etiology , diagnostic approach Delayed puberty , etiology , diagnostic approach
Delayed puberty , etiology , diagnostic approach Aftab Siddiqui
 
Short stature indication of growth hormone therapy
Short stature indication of growth hormone therapyShort stature indication of growth hormone therapy
Short stature indication of growth hormone therapyAftab Siddiqui
 
Pediatric hypertension
Pediatric hypertensionPediatric hypertension
Pediatric hypertensionTauhid Iqbali
 
Persistent diarrhea in children 2021
Persistent diarrhea in children 2021Persistent diarrhea in children 2021
Persistent diarrhea in children 2021Imran Iqbal
 
Approach to a child with hematuria
Approach to a child with hematuriaApproach to a child with hematuria
Approach to a child with hematuriaSunil Agrawal
 
Short Stature.pptx
Short Stature.pptxShort Stature.pptx
Short Stature.pptxJwan AlSofi
 
Growth assessment and monitoring
Growth assessment and monitoringGrowth assessment and monitoring
Growth assessment and monitoringTauhid Iqbali
 
Introduction to a child with proteinuria
Introduction to a child with proteinuriaIntroduction to a child with proteinuria
Introduction to a child with proteinuriaDr. Saad Saleh Al Ani
 
Approach to tall stature
Approach to tall statureApproach to tall stature
Approach to tall statureDr Inayat Ullah
 

Tendances (20)

Short stature
Short statureShort stature
Short stature
 
Short stature
Short statureShort stature
Short stature
 
Short Stature
Short StatureShort Stature
Short Stature
 
Shortstature sandip
Shortstature sandipShortstature sandip
Shortstature sandip
 
Childhood hypertension
Childhood  hypertensionChildhood  hypertension
Childhood hypertension
 
Delayed puberty , etiology , diagnostic approach
Delayed puberty , etiology , diagnostic approach Delayed puberty , etiology , diagnostic approach
Delayed puberty , etiology , diagnostic approach
 
Short stature indication of growth hormone therapy
Short stature indication of growth hormone therapyShort stature indication of growth hormone therapy
Short stature indication of growth hormone therapy
 
Delayed Puberty
Delayed Puberty Delayed Puberty
Delayed Puberty
 
Short stature
Short statureShort stature
Short stature
 
Pediatric hypertension
Pediatric hypertensionPediatric hypertension
Pediatric hypertension
 
Short stature
Short statureShort stature
Short stature
 
Persistent diarrhea in children 2021
Persistent diarrhea in children 2021Persistent diarrhea in children 2021
Persistent diarrhea in children 2021
 
Hematuria In Children
Hematuria In ChildrenHematuria In Children
Hematuria In Children
 
Approach to a child with hematuria
Approach to a child with hematuriaApproach to a child with hematuria
Approach to a child with hematuria
 
Evaluation of short stature
Evaluation of short statureEvaluation of short stature
Evaluation of short stature
 
Short Stature.pptx
Short Stature.pptxShort Stature.pptx
Short Stature.pptx
 
Growth assessment and monitoring
Growth assessment and monitoringGrowth assessment and monitoring
Growth assessment and monitoring
 
Growth Disorders
Growth DisordersGrowth Disorders
Growth Disorders
 
Introduction to a child with proteinuria
Introduction to a child with proteinuriaIntroduction to a child with proteinuria
Introduction to a child with proteinuria
 
Approach to tall stature
Approach to tall statureApproach to tall stature
Approach to tall stature
 

Similaire à Approach to a child with short stature AG

Short stature ppt
Short stature pptShort stature ppt
Short stature pptdivyaanair
 
Short stature definition and approach
Short stature definition and approachShort stature definition and approach
Short stature definition and approachAbdulmoein AlAgha
 
Approach to short stature ppt.pptx
Approach to short stature ppt.pptxApproach to short stature ppt.pptx
Approach to short stature ppt.pptxRaheelAhmed210939
 
Approach to short stature 160614135523
Approach to short stature 160614135523Approach to short stature 160614135523
Approach to short stature 160614135523Mohammed Ayad
 
An approach to short stature in children td
An approach to short stature in children tdAn approach to short stature in children td
An approach to short stature in children tdsahasra25
 
growthdisorders-141014114149-conversion-gate02.pdf
growthdisorders-141014114149-conversion-gate02.pdfgrowthdisorders-141014114149-conversion-gate02.pdf
growthdisorders-141014114149-conversion-gate02.pdfsaadSaad48389
 
Sssandip 131119110758-phpapp01
Sssandip 131119110758-phpapp01Sssandip 131119110758-phpapp01
Sssandip 131119110758-phpapp01Muhammad Zafar
 
Growth Disorders.pptx
Growth Disorders.pptxGrowth Disorders.pptx
Growth Disorders.pptxDrPNatarajan2
 
Growth Disorders.pptx
Growth Disorders.pptxGrowth Disorders.pptx
Growth Disorders.pptxDrPNatarajan2
 
Short Stature and Poor Growth - Westchester Health Pediatrics
Short Stature and Poor Growth - Westchester Health PediatricsShort Stature and Poor Growth - Westchester Health Pediatrics
Short Stature and Poor Growth - Westchester Health PediatricsWestchester Health Pediatrics
 
Short stature Dr.M.Sucindar
Short stature   Dr.M.SucindarShort stature   Dr.M.Sucindar
Short stature Dr.M.SucindarSucindar M
 
Endocrine series Part 1
Endocrine series Part 1 Endocrine series Part 1
Endocrine series Part 1 akshatusa
 
Short stature (14).pptx
Short stature (14).pptxShort stature (14).pptx
Short stature (14).pptxLIVINGALONE1
 

Similaire à Approach to a child with short stature AG (20)

Short stature ppt
Short stature pptShort stature ppt
Short stature ppt
 
Disorders of growth
Disorders of growthDisorders of growth
Disorders of growth
 
Short stature definition and approach
Short stature definition and approachShort stature definition and approach
Short stature definition and approach
 
Approach to short stature ppt.pptx
Approach to short stature ppt.pptxApproach to short stature ppt.pptx
Approach to short stature ppt.pptx
 
SST
SSTSST
SST
 
Short stature
Short stature Short stature
Short stature
 
Approach to short stature 160614135523
Approach to short stature 160614135523Approach to short stature 160614135523
Approach to short stature 160614135523
 
An approach to short stature in children td
An approach to short stature in children tdAn approach to short stature in children td
An approach to short stature in children td
 
growthdisorders-141014114149-conversion-gate02.pdf
growthdisorders-141014114149-conversion-gate02.pdfgrowthdisorders-141014114149-conversion-gate02.pdf
growthdisorders-141014114149-conversion-gate02.pdf
 
Sssandip 131119110758-phpapp01
Sssandip 131119110758-phpapp01Sssandip 131119110758-phpapp01
Sssandip 131119110758-phpapp01
 
Growth Disorders.pptx
Growth Disorders.pptxGrowth Disorders.pptx
Growth Disorders.pptx
 
Growth Disorders.pptx
Growth Disorders.pptxGrowth Disorders.pptx
Growth Disorders.pptx
 
Short Stature and Poor Growth - Westchester Health Pediatrics
Short Stature and Poor Growth - Westchester Health PediatricsShort Stature and Poor Growth - Westchester Health Pediatrics
Short Stature and Poor Growth - Westchester Health Pediatrics
 
Short stature Dr.M.Sucindar
Short stature   Dr.M.SucindarShort stature   Dr.M.Sucindar
Short stature Dr.M.Sucindar
 
Short staure.Paeds 2.pptx
Short staure.Paeds  2.pptxShort staure.Paeds  2.pptx
Short staure.Paeds 2.pptx
 
Short staure.Paeds 2.pptx
Short staure.Paeds  2.pptxShort staure.Paeds  2.pptx
Short staure.Paeds 2.pptx
 
short stature
short statureshort stature
short stature
 
Endocrine series Part 1
Endocrine series Part 1 Endocrine series Part 1
Endocrine series Part 1
 
Short stature
Short statureShort stature
Short stature
 
Short stature (14).pptx
Short stature (14).pptxShort stature (14).pptx
Short stature (14).pptx
 

Plus de Akshay Golwalkar

Systematic approach to the seriously ill or injured child AG
Systematic approach to the seriously ill or injured child AGSystematic approach to the seriously ill or injured child AG
Systematic approach to the seriously ill or injured child AGAkshay Golwalkar
 
Seizures & epilipsy in chilldren pediatrics AG
Seizures & epilipsy in chilldren pediatrics AGSeizures & epilipsy in chilldren pediatrics AG
Seizures & epilipsy in chilldren pediatrics AGAkshay Golwalkar
 
Rheumatic valvular heart disease pediatrics AG
Rheumatic valvular heart disease pediatrics AGRheumatic valvular heart disease pediatrics AG
Rheumatic valvular heart disease pediatrics AGAkshay Golwalkar
 
Recognition & management of bradycardia pediatrics AG
Recognition & management of bradycardia pediatrics AGRecognition & management of bradycardia pediatrics AG
Recognition & management of bradycardia pediatrics AGAkshay Golwalkar
 
Pediatric Neurological emergencies & stabilization AG
Pediatric Neurological emergencies & stabilization AGPediatric Neurological emergencies & stabilization AG
Pediatric Neurological emergencies & stabilization AGAkshay Golwalkar
 
Neonatal resuscitation 2012 AG
Neonatal resuscitation 2012 AGNeonatal resuscitation 2012 AG
Neonatal resuscitation 2012 AGAkshay Golwalkar
 
Maintainance & replacement fluid therapy pediatrics AG
Maintainance & replacement fluid therapy pediatrics AGMaintainance & replacement fluid therapy pediatrics AG
Maintainance & replacement fluid therapy pediatrics AGAkshay Golwalkar
 
Acute gastroenteritis in children AG
Acute gastroenteritis in children AGAcute gastroenteritis in children AG
Acute gastroenteritis in children AGAkshay Golwalkar
 

Plus de Akshay Golwalkar (8)

Systematic approach to the seriously ill or injured child AG
Systematic approach to the seriously ill or injured child AGSystematic approach to the seriously ill or injured child AG
Systematic approach to the seriously ill or injured child AG
 
Seizures & epilipsy in chilldren pediatrics AG
Seizures & epilipsy in chilldren pediatrics AGSeizures & epilipsy in chilldren pediatrics AG
Seizures & epilipsy in chilldren pediatrics AG
 
Rheumatic valvular heart disease pediatrics AG
Rheumatic valvular heart disease pediatrics AGRheumatic valvular heart disease pediatrics AG
Rheumatic valvular heart disease pediatrics AG
 
Recognition & management of bradycardia pediatrics AG
Recognition & management of bradycardia pediatrics AGRecognition & management of bradycardia pediatrics AG
Recognition & management of bradycardia pediatrics AG
 
Pediatric Neurological emergencies & stabilization AG
Pediatric Neurological emergencies & stabilization AGPediatric Neurological emergencies & stabilization AG
Pediatric Neurological emergencies & stabilization AG
 
Neonatal resuscitation 2012 AG
Neonatal resuscitation 2012 AGNeonatal resuscitation 2012 AG
Neonatal resuscitation 2012 AG
 
Maintainance & replacement fluid therapy pediatrics AG
Maintainance & replacement fluid therapy pediatrics AGMaintainance & replacement fluid therapy pediatrics AG
Maintainance & replacement fluid therapy pediatrics AG
 
Acute gastroenteritis in children AG
Acute gastroenteritis in children AGAcute gastroenteritis in children AG
Acute gastroenteritis in children AG
 

Dernier

SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptMumux Mirani
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...MehranMouzam
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptkedirjemalharun
 
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMAANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMADivya Kanojiya
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATROKanhu Charan
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseSreenivasa Reddy Thalla
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAAjennyeacort
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdfDolisha Warbi
 
low cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptxlow cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptxdrashraf369
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
 
systemic bacteriology (7)............pptx
systemic bacteriology (7)............pptxsystemic bacteriology (7)............pptx
systemic bacteriology (7)............pptxEyobAlemu11
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxDr. Dheeraj Kumar
 
Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsMedicoseAcademics
 
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxPERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxdrashraf369
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Badalona Serveis Assistencials
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdfDolisha Warbi
 

Dernier (20)

SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.ppt
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.ppt
 
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMAANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies Disease
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
 
low cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptxlow cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptx
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
 
Epilepsy
EpilepsyEpilepsy
Epilepsy
 
systemic bacteriology (7)............pptx
systemic bacteriology (7)............pptxsystemic bacteriology (7)............pptx
systemic bacteriology (7)............pptx
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptx
 
Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes Functions
 
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxPERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
 

Approach to a child with short stature AG

  • 1. Approach To A Child With Short Stature Moderated by Dr. Mohd. Haseeb Sir Presented by Dr. Akshay Golwalkar
  • 2. Why we need to concern? BECAUSE………………….. IT CAN BE A SIGN OF DISEASE, DISABILITY & A SOCIAL STIGMA CAUSING PSYCHOLOGICAL STRESS 
  • 3. Definition* Height below 3rd centile or less than 2 standard deviations below the median height for that age & sex according to the population standard OR Even if the height is within the normal percentiles but growth velocity is consistently below 25th percentile over 6-12 months of observation or Excessively short for mid mid parental or target height Males Age (y ) 30 34 38 42 46 50 54 58 62 66 70 74 78 Height(in) Height(cm) 2 4 6 8 10 12 14 16 18 20 70 80 90 100 110 120 130 140 150 160 170 180 190 200 0 +2 +1 -1 -2 -2.0 SD (2.3 percentile) *Essential Pediatrics, 7th Edition OP Ghai; IAP spatiality series Endocrinology 2nd edition
  • 4. Approximately 3% children in any population will be short* Approximately half will be physiological ( familial or constitutional ) & half will be pathological short stature* Most common cause is malnutrition in developing countries* Familial or constitutional is the leading cause in developed countries* *IAP spatiality series Endocrinology 2nd edition
  • 5. Growth Physiology Growth Environment HormonesGenetic factors Dietary factors •Growth hormone •Thyroid hormone •Gonadotrophins
  • 6. Factors affecting height Intra uterine Growth factors Nutrition Thyroid harmone Growth Hormone FSH LH GH Thyroid Birth 1 year 2 years 4years 8years Puberty Adult
  • 7. Endocrinology of Postnatal Growth Deficiency of thyroxin blunts GH secretion. GROWTH Linear Growth Ponderal Growth Skeletal maturation & Bone Growth Linear Growth Increased Growth Velocity @ puberty
  • 8. Etiology of short stature* Physiological – Familial – Constitutional short stature Pathological – undernutrition – Chronic systemic illness – Hormonal deficiency states – Psychosocial dwarfism – SGA – Skeletal dysplasias – Genetic syndromes *Essential Pediatrics, 7th Edition OP Ghai; IAP spatiality series Endocrinology 2nd edition
  • 9. Familial Vs Constitutional* Feature Familial Short Stature Constitutional Short Stature 1) Sex Both equally affected More common in boys 2) Family History Of short stature Of delayed puberty 3) Height Velocity Normal Normal 4) Puberty Normal Delayed 5) Bone Age Normal Less than chronological age 6) Final Height Short, but normal for target height Normal *IAP spatiality series Endocrinology 2nd edition
  • 10.
  • 11. Approach to a child with short stature History & “observation” Anthropometric measurements Plotting on growth chart Physical examination workup
  • 12. History Birth history Nutritional history Chronic disease history (asthma, CHD, CLD,CRF, chronic diarrhea) Drugs….chronic steroid therapy Family history
  • 13. History Etiology History of delay of puberty in parents Constitutional delay of growth Low Birth Weight SGA Neonatal hypoglycemia, jaundice, micropenis GH deficiency Dietary intake Under nutrition Headache, vomiting, visual problem Pituitary/ hypothalamic SOL Lethargy, constipation, weight gain Hypothyroidism Polyuria CRF, RTA Social history Psychosocial dwarfism Diarrhea, greasy stools Malabsorption Clues to etiology from history
  • 14. Pointer Etiology Midline defects, micropenis, Frontal bossing, depressed nasal bridge, crowded teeth, GH deficiency Rickets Renal failure, RTA, malabsorption Pallor Renal failure, malabsorption, nutritional anemia Malnutrition PEM, malabsorption, celiac disease, cystic fibrosis Obesity Hypothyroidism, Cushing syndrome, Prader Willi syndrome Metacarpal shortening Turner syndrome, pseudohypoparathyroidism Cardiac murmur Congenital heart disease, Turner syndrome Mental retardation Hypothyroidism, Down/ Turner syndrome, pseudohypoparathyroidism Pointers to etiology of short stature
  • 15. 1) Accurate height measurement Below 2 yrs*- supine length with infantometer. Assessment of a child with short stature *IAP spatiality series Endocrinology 2nd edition
  • 16. Assessment of a child with short stature For older children- Harpenden Stadiometer
  • 17. Height measurements Without footwear Heels & back touching the wall Looking straight ahead
  • 19. Increments in Height* Age Increase in height Birth 50cm 1st yr age 25cm 2nd yr age 10cm 3rd yr age 7.5cm 4th yr age 5cm 5th yr age 5cm/year *IAP spatiality series Endocrinology 2nd edition
  • 20. Growth Velocity* The most critical factor in evaluating the growth is determining GROWTH VELOCITY. Observation of childs height pattern in the form of “CROSSING PERCENTILE LINES” on a linear growth curve is the simplest method of observing abnormal growth velocity.* *IAP spatiality series Endocrinology 2nd edition
  • 21. At least 3 measurements with preferably 6 months interval in between is necessary to comment on growth pattern.* *IAP spatiality series Endocrinology 2nd edition Growth Velocity*
  • 22. Growth Monitoring* Age Ht/Length Wt Head circumference Others Birth Yes Yes Yes -- 1.5, 3.5 6, 9, 15 mths Yes Yes Yes -- 1.5 to 3 yrs 6 monthly 6 monthly 6 monthly Mid arm 3.5 to 5.5 yrs 6 monthly 6 monthly -- 6 to 8 yrs 6 monthly 6 monthly -- BMI & SMR 9 to 18 yrs Yearly Yearly -- BMI & SMR yearly *IAP spatiality series Endocrinology 2nd edition
  • 23. Target height* Target height in cm for a girl = [(mother's height in cm + father's height in cm) /2] - 6.5 cm Target height in cm for a boy = [(mother's height in cm + father's height in cm) /2] + 6.5 cm *IAP spatiality series Endocrinology 2nd edition
  • 24. Short Child That Looks Normal* Normal growth velocity Low growth velocity Low birth weight Growth delay Idiopathic SS Chronic systemic disease Endocrine disorder Genetic, chromosomal Psychosocial Calculate the target height Within Target RangeNot Within Target Range Watch GV Observe – GV Normal
  • 25. Assessment of body proportion Lower segment (LS) pubic symphysis to ground Upper segment (US) total height/length – LS US to LS ratio is 1.7 at birth decreases by 0.1 every year to reach 1 at 7 to 10 years of age.* *IAP spatiality series Endocrinology 2nd edition
  • 26. Arm span Upper segment: Lower segment ratio Increase : – Achondroplasia – Skeletal dyspalsias – untreated hypothyroidism Decreases : – Short trunk (scoliosis) – Short neck (klippel-Feil syndrome) – Arachnodactyly (Marfan’s, homocystinuria) Assessment of body proportion
  • 27.
  • 28.
  • 29.
  • 30. Physical examination Weight measurement (fat & short….endocrine, thin & short……under nutrition or chronic illness) Systemic examination to rule out systemic illness skeletal system examination including spine Dysmorphic features Tanner staging
  • 31. Clues to etiology from examination* Examination finding Etiology Disproportion Skeletal dysplasia, rickets, hypothyroidism Dimorphism Congenital syndromes Pallor Chronic anemia, chronic renal failure Hypertension Chronic renal failure Frontal bossing, depressed nasal bridge, crowed teeth, small penis Growth hormone deficiency Goiter, coarse skin Hypothyroidism Central obesity, striae Cushing syndrome *Essential Pediatrics, 7th Edition OP Ghai;
  • 32. Workup for short stature Level 1* ( essential investigations): Complete hemogram with ESR Urinalysis Stool Blood BONE AGE *IAP spatiality series Endocrinology 2nd edition
  • 33. Bone age assessment should be done in all children with short stature Appearance of various epiphyseal centers & fusion of epiphyses with metaphyses tells about the skeletal maturity of the child Bone Age (BA)
  • 34. What does bone age tell you? Skeletal maturity Correlates closely with SMR Speaks for remaining growth potential Helps in adult height prediction Bone age delay of more than 2 SD i.e. about 2 years is significant
  • 35. Methods of bone age assessment Tanner White House Greulich and Pyle
  • 36. TW Method - 13 Bones
  • 37. G & P Method Patient’s film is compared with the standard of the same sex and nearest age It is next compared with adjacent standard, both older and younger to get the closest match
  • 38. Bone age gives an idea as to what proportion of adult height has been achieved by the child & what is remaining potential for height gain* BA is delayed compared to chronological age in almost all causes of short stature* Exceptions: Familial short stature, Precocious puberty *IAP spatiality series Endocrinology 2nd edition
  • 39. Delayed bone age Constitutional short stature Hypothyroidism Celiac disease GH deficiency
  • 40. Level 2*: Serum thyroxine, TSH Karyotype to rule out Turner syndrome in girls If above investigations are normal and height between -2 to -3 SD Observe height velocity for 6-12 months Workup for short stature if Level 1 investigations are normal and bone age is delayed proceeds to level 2* *IAP spatiality series Endocrinology 2nd edition
  • 41. HYPOTHYROIDISM Short, stocky child, dull looking, puffy face. Thickened skin giving myxomatous appearance, cold intolerance. Protuberant abdomen with umbilical hernia Infantile sexual development & delayed puberty Bone age markedly delayed Diagnosis- Low T4 levels, high TSH levels* *IAP spatiality series Endocrinology 2nd edition
  • 42. HYPOTHYROIDISM CONGENITAL (UNTREATED):  Slow growth vel.  Delayed BA  Constipation  Mental retardation unless treated at 2-3 months. ACQUIRED(UNTREATED)  Asymptomatic  Delayed growth  Constipation  Normal IQ if developed after 2yrs of age  Dry skin
  • 43. Ideally every neonate should be screened for TSH levels before discharging from nursery.* Regardless of symptoms all children with significant short stature should be screened for hypothyroidism.* Rx: thyroxine according to the age appopriate dosage HYPOTHYROIDISM *IAP spatiality series Endocrinology 2nd edition
  • 44.
  • 45. Turners syndrome Short stature may be the only clinical manifestation. Karyotyping should be considered in a short female child with pubertal delay. SHOX gene which is required for the normal growth is present only in a half a dose in these children
  • 46.  Webbed neck  Short metacarpals  Shield shaped chest  Hyperconvex finger n toe nails  Cubitus valgus with wide carrying angle of arms  Gonadal dysgenesis with incomplete or absent puberty  No pubertal growth spurt.
  • 47.
  • 48.
  • 49.
  • 50. Level 3*: GH stimulation test with Clonidine or insulin & serum insulin like GF-1 levels Neuroimaging Celiac serology ( anti- endomysial or anti- tissue transglutaminase antibodies) Duodenal biopsy If height < -3 SD → proceeds to level 3 investigations* *IAP spatiality series Endocrinology 2nd edition
  • 51. GROWTH HORMONE DEFICIENCY(GHD) Normal length & weight at birth. Growth delay seen >1yr of age BA < CA by at least 2 yrs Normal intelligence & delayed BA. Infantile gonadal development
  • 52. Growth hormone actions Growth Hormone GH receptors Liver Synthesis of IGF1 Metabolic effects IGF receptors Growth Hormone GH receptors GH receptors Liver Synthesis of IGF1 Proliferation of Cells Cellular growth Linear growth Metabolic effects (Anabolic) IGF receptors
  • 53. GROWTH HORMONE DEFICIENCY(GHD) CONGENITAL: -Perinatal asphyxia, -CNS malformations (septo optic dysplasia) ACQUIRED -idiopathic -tumors ( craniopharyngioma, glioma, germinoma) -trauma/surgery -cns infection/irradiation
  • 54. Physical features Cherubic face; fair complexion Normal IQ Frontal bossing Midfacial crowding Truncal obesity Micropenis
  • 55. Workup for GH def GH deficiency is diagnosed by a low level of serum insulinlike growth factor-1 (IGF-1) in the presence of deficiency of 3 or more pituitary hormones*. Patients who have deficiency of 2 or less pituitary hormones or pituitary-hypothalamic disease with low IGF-1 levels require stimulation tests to establish the diagnosis of GH deficiency*. *Hartman ML, Crowe BJ, Biller BM, Ho KK, Clemmons DR, Chipman JJ. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency?. J Clin Endocrinol Metab. Feb 2002;87(2):477- 85.
  • 56. Workup for GH def GH stimulation test Insulin-induced hypoglycemia is the most powerful stimulus for GH secretion; however, this test also carries the greatest potential for harm*. Alternate GH stimulants: Arginine*, levodopa, Propranolol with glucagon, Exercise, Clonidine, Epinephrine. *Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML,. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. Jun 2011;96(6):1587-609
  • 57. GH stimulation test INTERPRETATION: Peak stimulated growth hormone conc. <5.1ng/ml* in response to GH stimulation test or <11.1 ng/ml in response to combined Arg- GHRH stimulation test with patients having BMI less than 25*. *Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML,. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. Jun 2011;96(6):1587-609
  • 58. IGF-1 and IFGBP-3 measurement* IGFBP-3 and IGF-1 serum levels represent a stable and integrated measurement of GH production and tissue effects IGF-1 have superior diagnostic sensitivity and specificity compared with IGFBP 3. The combination of IGF-1 and IGFBP-3 measurements is superior when compared to individual tests Workup for GH def *IAP spatiality series Endocrinology 2nd edition
  • 59. Interpretation of results* If IGF-1 and IGBP-3 level are normal then it shows that GH level is also normal (no need for GH testing) If IGF-1 and IGBP-3 level are low then it may be due to GH def or GH resistance-----go for GH basal level and after stimulation If GH also low then GH def, if normal or high then GH resistance ( Primary IGF-1 def) *IAP spatiality series Endocrinology 2nd edition
  • 60. growth hormone therapy* Currently approved as per FDA IN: GHD TURNERS SYNDROME RENAL INSUFFIENCY PRADER WILLE SYNDROME NORMAL CHILDREN WITH HEIGHT <2.4 SD SGA who have not reached 5th centile by 2yrs. Shox (short stature homeobox gene)deficiency. *IAP spatiality series Endocrinology 2nd edition
  • 61. GH THERAPY* DOSE: 0.1U/KG/DAY s.c. at night time Follow up & watch for at least one year before starting the treatment. Earlier is always better & ideal is 3-4yrs Never delay beyond 7-8yrs Usually growth velocity is maximum in first year of therapy. *IAP spatiality series Endocrinology 2nd edition
  • 62. Devices: Freeze dried – commonest Liquid prep- easy to administer GH THERAPY
  • 64. G H THERAPY  Routes of administration: S.c- currently using Intranasal- under trials Timing: 2-3 times/wk  Response to Rx: Max response in 1st year with growth velocity >95th percentile With each increasing year the growth rate tends to decline. If falls <25th percentile: assess compliance before increasing dose.
  • 65. CRITERIA FOR STOPPING Rx:*  Decision by patient that he/she is tall enough  Growth rate <1 inch/year BA >14YRS in girls & 16yrs in boys. *IAP spatiality series Endocrinology 2nd edition
  • 66. FOLLOWUP:*  required as there is risk of :primary hypothyroidism / adrenal insuffiency so periodic follow up needed. SIDE EFFECTS:*  Pseudotumour cerebri, hyperglycemia, acute pancreatitis, liver abnormalities, gynaecomastia, *IAP spatiality series Endocrinology 2nd edition
  • 67.
  • 68. Take Home Message Take height properly along with the height of parents Plot on Growth Charts and find out the target centile Determine the growth velocity by follow up at least after 6 months A systematic approach and simple tests like bone age usually reduce the need & hence cost of further investigations For dynamic stimulation tests refer the child to specialist centres
  • 69. SHORT STATURE Dysmorphic Normal •Russle Silver •Noonan’s •Turner syndrome •Downs syndrome •Prader Willi •Pseudo- hypoparathyroidism Proportionate Dis- Proportionate •Constitutional •Familial/genetic •IUGR •Ch Malnutrition •Celiac Disease •Chronic systemic disease (CRF, CLD) •GH Deficiency •Hypogonadism •Hypothyroidism •Osteogenesis imperfecta •Achodroplasia •Rickets •Metabolic and storage disorders (short spine)
  • 70. Level 1 ( essential investigations): 1.Complete hemogram with ESR 2.BONE AGE 3.Urinalysis ( Microscopy, pH, Osmolality) 4.Stool ( parasites, steatorrhea, occult blood) 5.Blood ( RFT, Calcium, Phosphate, alkaline phosphatase, venous gas, fasting sugar, albumin, transaminases) Level 2 (investigations for short stature) 1.Serum thyroxin, TSH 2.Karyotype to rule out Turner syndrome in girls Above is normal and bone age is delayed proceeds to level 2
  • 71. • If above investigations are normal and height between -2 to -3→ observe height velocity for 6-12 months • If height < -3 SD → proceeds to level 3 investigations

Notes de l'éditeur

  1. Height below 3rd centile or less than 2 standard deviations below the median height for that age & sex according to the population standard OR Even if the height is within the normal percentiles but growth velocity is consistently below 25th percentile over 6-12 months of observation or Excessively short for mid mid parental or target height The term ‘Dwarfism’ is no longer used for short stature It should not be confused with FTT as it is associated with greater impairment in wt.gain than linear growth resulting in decresd W/H.& THE LINEAR GROWTH affected is almost always SECONDARY.
  2. Genetic potential Inadequate food choices and intake: Toddlers are notoriously picky leading to macro & micro nutrient deficiency Psychosocial dwarfism emotional deprivation children from unhappy homes emotional needs of child totally neglected characterized by functional hypopitutirism with low IGF1, Other behavioural disorders: enuresis, encorpresis, sleep & appetite disturbances, crying spasms, tantrums Dental eruptions & sexual development delayed Neglect: inadequate intake equals inadequate resources for growth Growing evidence that growth hormone, like the rest of the HPA, is affected by stress levels Psychological dwarfism: obscene extreme of neglect, marked by short stature, bizarre behavior and limited speech
  3. PRENATAL GROWTH: Uterine function & size, maternal nutrition, insulin,IGF/BP POSTNATAL GROWTH: GH& THYROXINE Rapid linear growth velocity initially that declines progressively after birth to 3 yrs. 25cms  12.5cms->8cm/yr. 3YEARS TO PUBETY: GH& THYROID HORMONE Constant linear growth @4-7cm/yr. PUBERTY: Sex steroids(estrogen&testosterone) in concert with GH,THYROID,&NUTRTION Acceleration of growth pubertal growth spurt. Spontaneous growth hormone elevation in response to sex steroids. First sign of puberty in females preceeds the first sign of puberty in males by 6months. Pubertal growth spurt in females is 2 years earlier than males but the peak height velocity is slower in females than males(8.3cm/yr <9.5cm/yr) resulting in on an average of 13cm difference in between them.
  4. Familial short stature – by defn child is short but is normal acc to his own genetic potential as determined by parents height. Growth velocity is normal. Bone age equals chronological age. Constitutional delay – born with normal length & weight grow normally upto 6 to 12 mths of age then develeration so ht & wt fall 3rd percentile puberty & adoloscent growth spout late..bone age lower than chrono age but correlate to height age. h/o of delayed puberty in parents Renal Rta, crf, steroid dep neph synd Cardio pulm CHD, cystic fibrosis, asthama GI hepatic malabsorption CLD Infections Gh, thyroid, cushing, pseudohypoparathyroidism, precocious or delayed puberty Psychosocial dwarfism emotional deprivation children from unhappy homes emotional needs of child totally neglected characterized by functional hypopitutirism with low IGF1, Other behavioural disorders: enuresis, encorpresis, sleep & appetite disturbances, crying spasms, tantrums Dental eruptions & sexual development delayed Skeletal dysplasias achandroplasia Genetic turner downs
  5.  hallmarks of familial (genetic) short stature is normal bone age, normal growth velocity, and predicted adult height appropriate to the familial pattern By contrast, constitutional growth delay is characterized by delayed bone age and predicted adult height appropriate to the familial pattern  Patients with constitutional growth delay typically have a first or second-degree relative with constitutional growth delay (menarche older than 15 y, adult height attained in male relatives when older than 18 y)
  6. Infanto meter: Child should be relaxed Head should be placed against an inflexible board. Legs fully extended Feet placed perpendicular onto movable flat board.
  7. Frankfurt plane [line joining inferior orbital margin to ext auditory meatus] paralel to ground
  8. Measured in cm/yr.
  9. Arm span shorter than length at 2..5 cm at birth equals at 11 yrs of age then greater than height
  10. klippel-Feil syndrome
  11. Marfan’s Arm span shorter than length at 2..5 cm at birth equals at 11 yrs of age then greater than height
  12. Weight measurement -W/A >H/A i.e. fat & short- Endocrine. -H/A> W/A but both are below the chronological age with thin & short- Under nutrition / chronic illness. Systemic examination to rule out systemic illness skeletal system examination including spine Dysmorphic features Tanner staging
  13. CBC with ESR for anaemia & its probable cause, esr for chronic infections Urinalysis ( Microscopy, pH, Osmolality) Stool ( parasites, steatorrhea, occult blood) Blood ( RFT, Calcium, Phosphate, alkaline phosphatase, venous gas, fasting sugar, albumin, transaminases)
  14. Tanner White House Ulanr & radial epiphysis Carpel bones Capitate & Hamate 1st year & cartilage discs appear fuse at puberty Triquetral 2nd yr Lunate 3rd yr Scaphoid trapizium & trapezoid 6th yr Pisifform 12th yr
  15. Familial short stature BA equals CA , precocious puberty BA exceds CA
  16. Shox (short stature homeobox gene)deficiency.
  17. Webbed neck Short metacarpals Shield shaped chest Hyperconvex finger n toe nails Cubitus valgus with wide carrying angle of arms Gonadal dysgenesis with incomplete or absent puberty No pubertal growth spurt.
  18. Webbed neck Short metacarpals Shield shaped chest Hyperconvex finger n toe nails Cubitus valgus with wide carrying angle of arms Gonadal dysgenesis with incomplete or absent puberty No pubertal growth spurt.
  19. Turner – pterygium coli
  20. endogenous GH is secreted in a pulsatile fashion. These intermittent peaks are greatest after exercise, meals, and during deep sleep. Therefore, measuring a single random serum GH value is of no use in the evaluation of the short child. random serum GH value of more than 10 mg/dL generally excludes GHD, a random low serum GH concentration does not confirm the diagnosis
  21. In the ITT, insulin is administered intravenously at a dose of 0.1 U/kg (time 0) to produce a lowering of the plasma glucose level to less than 40 mg/dL (2.2 mmol/L). Glucose levels can be monitored by capillary samples every 15 minutes and once symptoms of hypoglycemia develop. A repeated dose of insulin can be administered if hypoglycemia does not develop by 30-60 minutes. Serum glucose and serum GH levels are measured at times 0, 15, 30, 60, 90, and 120 minutes after administering insulin. The GHRH-arginine can be used as an alternative to the ITT.[22] GHRH is administered intravenously at a dose of 1 µg/kg body weight (time 0) followed by an intravenous infusion of 0.5 g/kg body weight (not to exceed 30 g) of arginine over 30 minutes. Serum GH is measured at -30, 0, 30, 60, 90, and 120 minutes. Because body mass index (BMI) can influence the GH response, the following criteria are used to establish the diagnosis of GH deficiency when using the GHRH-arginine test[
  22. Igfbp insulin like growth factor binding protein